Design of a dual ERK5 kinase activation and autophosphorylation inhibitor to block cancer stem cell activity
Related Experiment Video
Updated: Dec 8, 2025

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening
Published on: May 12, 2017
Samanth R Kedika1, Satya P Shukla1, D Gomika Udugamasooriya2
1Department of Pharmacological & Pharmaceutical Sciences, University of Houston, 4849 Calhoun Rd, Health Building 2, Room 7033, Houston, TX 77204-5037, USA.
Abstract:
The importance of ERK5 kinase signaling in tumorigenicity, metastasis, and drug resistance of cancer stem cells (CSCs) has been recognized recently, and we report a unique dual inhibitor that blocks binding of the ERK5 activator and ERK5 autophosphorylation simultaneously. The conventional ATP-binding site inhibitors have not yet yielded expected level of anti-cancer effects, due to complexities in converting ERK5 activation into CSC biological effects. We designed the first ERK5-targeted anti-CSC dual active hetero-bivalent inhibitor that blocks the regulatory peptide interaction involved in ERK5 kinase activation and that simultaneously inhibits the conventional ATP-binding pocket as well. We utilized two assay systems to independently prove disruption of these two ERK5 activities via a single compound. We also showed that this compound inhibited CSC activities, such as colony formation, cell proliferation, and migration.
Insights
We developed a novel dual inhibitor targeting ERK5 kinase, crucial for cancer stem cell (CSC) survival and drug resistance. This compound simultaneously blocks ERK5 activation and its ATP-binding site, offering a new strategy against cancer progression.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- ERK5 kinase signaling is increasingly recognized for its role in cancer stem cell (CSC) tumorigenicity, metastasis, and drug resistance.
- Conventional ATP-binding site inhibitors for ERK5 have shown limited anti-cancer efficacy due to complex activation pathways.
- Targeting ERK5 activation mechanisms is crucial for developing effective anti-CSC therapies.
Purpose of the Study:
- To design and characterize the first dual-acting inhibitor targeting both ERK5 activation and its ATP-binding site.
- To investigate the compound's ability to disrupt ERK5 kinase activity through two distinct mechanisms simultaneously.
- To evaluate the efficacy of this dual inhibitor against key cancer stem cell functions.
Main Methods:
- Design of a novel hetero-bivalent inhibitor targeting ERK5.
- Utilized two independent assay systems to confirm dual inhibition of ERK5 activation and ATP-binding.
- Assessed the compound's impact on CSC proliferation, colony formation, and migration.
Main Results:
- Successfully designed a single compound that acts as a dual inhibitor of ERK5.
- Demonstrated simultaneous blockade of the ERK5 activator binding site and the ATP-binding pocket.
- The dual inhibitor significantly inhibited CSC colony formation, proliferation, and migration.
Conclusions:
- A novel dual-acting ERK5 inhibitor has been developed, targeting key CSC pathways.
- This compound effectively disrupts both ERK5 activation and kinase activity.
- The findings present a promising new therapeutic strategy for combating cancer stem cells and overcoming drug resistance.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...